Phase 2 Mesothelioma Trial, Recruiting NCT06477419 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT06477419
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your legal representative) are willing and able to sign a written consent form
  • You are 18 years old or older at the time of signing consent
  • You have been diagnosed with diffuse pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed through a tissue sample
  • You have already received at least one previous treatment for this cancer, such as platinum-based chemotherapy, pemetrexed, immunotherapy, or a combination of these
  • Your cancer can be measured on scans using standard medical measurement guidelines
  • You are willing to have a tissue biopsy taken before starting treatment and again at the start of the third treatment cycle, if it is safe and possible to do so
  • You are in good enough general health to carry out daily activities (as measured by standard medical scoring tools) (confirm with trial site)
  • Your blood counts, kidney function, liver function, and red blood cell levels meet the required levels shown in routine blood tests (confirm with trial site)
  • If you are able to become pregnant, you must be willing to use a highly effective form of birth control for at least one month before, during, and for two months after treatment ends

Who may not be able to join:

  • You are currently taking part in another clinical trial or have received an experimental treatment within the past 3 weeks
  • You have previously had a severe allergic reaction to irinotecan or to any ingredients in the study drug sacituzumab govitecan-hziy
  • You have received chemotherapy or immunotherapy within the last 3 weeks, or you are still experiencing significant side effects from a previous cancer treatment
  • You have a psychiatric condition or substance use problem that, in the doctor's opinion, would make it difficult for you to take part in the trial
  • You have another type of cancer that is growing or currently being treated (some early-stage or skin cancers may be exceptions — confirm with trial site)
  • You currently have an active hepatitis B infection (some people with a past hepatitis B history may still be eligible — confirm with trial site)
  • You currently have hepatitis C (people who have been successfully treated for hepatitis C may still be eligible — confirm with trial site)
  • You are HIV-positive with certain conditions, such as a low immune cell count, a recent serious infection, or your HIV is not well controlled (confirm with trial site)
  • You have had a heart attack, unstable chest pain, stroke, or heart bypass surgery within the past 6 months
  • You have moderate to severe heart failure, or were hospitalised for heart failure within the past 6 months
  • You are pregnant, breastfeeding, or able to become pregnant and are not using a highly effective form of birth control

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael Offin, MD, Memorial Sloan Kettering Cancer Center

Phone: 646-608-3763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 June 2024
Est. completion
21 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Overall Response Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov